Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 2/6 |
Past Performance | 6/6 |
Financial Health | 3/6 |
Dividends | 5/6 |
Merck & Co., Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$89.50 |
52 Week High | US$89.50 |
52 Week Low | US$69.41 |
Beta | 0.34 |
1 Month Change | 0% |
3 Month Change | 3.11% |
1 Year Change | n/a |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | 38.28% |
Recent News & Updates
Recent updates
Shareholder Returns
6MK | BG Pharmaceuticals | BG Market | |
---|---|---|---|
7D | 0% | -1.2% | 0.6% |
1Y | n/a | 6.0% | 15.8% |
Return vs Industry: Insufficient data to determine how 6MK performed against the BG Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how 6MK performed against the BG Market.
Price Volatility
6MK volatility | |
---|---|
6MK Average Weekly Movement | n/a |
Pharmaceuticals Industry Average Movement | 5.2% |
Market Average Movement | 3.8% |
10% most volatile stocks in BG Market | 7.1% |
10% least volatile stocks in BG Market | 2.2% |
Stable Share Price: 6MK has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 6MK's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1891 | 67,500 | Rob Davis | www.merck.com |
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.
Merck & Co., Inc. Fundamentals Summary
6MK fundamental statistics | |
---|---|
Market cap | €222.49b |
Earnings (TTM) | €16.97b |
Revenue (TTM) | €58.30b |
13.1x
P/E Ratio3.8x
P/S RatioIs 6MK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
6MK income statement (TTM) | |
---|---|
Revenue | US$57.17b |
Cost of Revenue | US$16.71b |
Gross Profit | US$40.46b |
Other Expenses | US$23.82b |
Earnings | US$16.64b |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
Oct 27, 2022
Earnings per share (EPS) | 6.57 |
Gross Margin | 70.77% |
Net Profit Margin | 29.11% |
Debt/Equity Ratio | 73.1% |
How did 6MK perform over the long term?
See historical performance and comparison